IL-17-producing T h (T h 17) comprise a distinct lineage of pro-inflammatory T h that are major contributors to autoimmune diseases. Treatment with IL-6 and transforming growth factor b (TGFb) induces naive CD4
Introduction
The Janus kinase (Jak)-signal transducers and activators of transcription (STAT) pathway was originally discovered through the study of IFN-induced signal transduction. Since then, a large number of cytokines, hormones and growth factors have been found to activate Jaks and STATs. Upon ligand binding, the STAT family is activated to form dimers, which translocate to the nucleus and bind to specific response elements in the promoters of target genes.
Until the discovery of the recently described T h 17 lineage, the adaptive CD4 + T-cell responses have been encompassed by the T h 1-T h 2 paradigm (1, 2) . The development of T h 1, which enhance the clearance of certain intracellular pathogens, is dependent on IFNc and IL-12 (3, 4) . It is now known that T h 1 generation is mediated by IFNcR signaling via STAT1, driving Tbet expression (5, 6) . The development of T h 2, which enhance the clearance of parasites or the generation of Igs, is dependent on IL-4 (7, 8) . The T h 1 and T h 2 populations can also be categorized by their distinct requirements for STAT molecules: STAT4 and STAT1 for T h 1 (5, 6, 9, 10) and STAT6 for T h 2 (11, 12) . Mice deficient in IL-17 are resistant to collagen-induced arthritis (CIA) (13) . The development of the IL-17-producing T cells, now termed T h 17, was initially shown to depend on the presence, during antigen stimulation, of IL-23 produced by the antigen-presenting cells (14) (15) (16) (17) . Although IL-23 has a key role in T h 17-mediated inflammation in vivo (18) , recent studies have demonstrated that the in vitro polarization of naive CD4
+ T cells toward the T h 17 lineage requires a combination of T cell antigen receptor stimulation and the cytokines transforming growth factor b (TGFb) and IL-6, but that it is independent of IL-23 (19, 20) . Additionally, it was previously reported that in vivo polarization of naive T cells toward the T h 17 lineage requires IL-6 and TGFb (19, 21) . Importantly, it is reported that IL-6 signaling suppressed in vitro regulatory T cell (Treg) development, suggesting reciprocal development pathways for the generation of T h 17 and Tregs (19) . However, it has not been shown whether these reciprocal development pathways also exist in in vivo situation. Recently, RORct was identified as a critical target of TGFb and IL-6 for the development of T h 17 (22) . However, it is not known if any STAT family 'in T cells' is critically involved in T h 17 development, although STAT3 is the major STAT that is activated by IL-6 and STAT3 is previously known to bind both the IL-17A and IL-17F promoters (18) and STAT3 depletion in hematopoietic stem cells as well as endothelial cells using Tie2-Cre mice (23) decreased T h 17 development (24) .
The IL-6R consists of a ligand-binding a-chain and the signal transducer gp130, which is shared among the receptors for the other IL-6 family cytokines (25, 26) . Binding of the IL-6 family cytokines to their receptors activates Jak, leading to the recruitment of two important signal-transducing molecules: Src homology region 2 domain-containing phosphatase 2 (SHP2) (protein tyrosine phosphatase 2) and STAT3. The gp130 subunit contains six tyrosines in its cytoplasmic region and transduces two major signaling pathways, which are dependent on these tyrosine residues: (i) Tyr759 for human gp130 (Tyr754 for mouse) is required for the tyrosine phosphorylation of SHP2 and (ii) any one of four tyrosines in the C-terminus (Tyr767, Tyr814, Tyr905 and Tyr915), which have a glutamine at position 3 of the tyrosine motif (YXXQ), is required for the tyrosine phosphorylation of STAT3 (25, 26) . Tyr759 is required for the tyrosine phosphorylation of SHP2 and the activation of Gab, extracellular signal-regulated kinase (ERK) and mitogen-activated protein kinase (MAPK). It is also shown to have a negative role in STAT3-mediated biological actions mediated by a STAT3 inhibitor, suppressor of cytokine signaling 3 (SOCS3) or SHP2 itself (25) . We previously established a series of knock-in mice expressing mutant gp130 defective in the SHP2/Gab/MAPK pathway (the F759 mouse), the STAT3-dependent pathway (the FxxQ mouse) or both (27) . We observed that the F759 mouse, lacking the SHP2/Gab/MAPK pathway, has splenomegaly and lymphadenopathy from an early age and develops autoimmune arthritis in later life (28, 29) . However, which IL-6-mediated pathway is critical for the development of T h 17, i.e. the SHP2/Gab/MAPK or the STAT3-dependent pathway in T cells, has not been studied.
We show here that the IL-6-gp130-mediated STAT3 pathway in T cells is required for RORct expression and the development of T h 17 with a minimum effect on in vivo Treg development at least in the steady state.
Methods

Mice
C57BL/6 mice were purchased from Japan SLC (Shizuoka, Japan). gp130 flox/flox mice were established previously (30) and crossed with lckCre transgenic mice. DBA-backcrossed F759 mice (more than eight times) were established by us. C57BL/6-backcrossed lckCre transgenic mice and STAT3 flox/ flox mice were obtained from S. Akira (31) (Osaka University). The gp130 F759/F759 knock-in mice, which carry a human version of gp130 (S710L), were established previously (27, 32) . IL-6 knockout (KO) mice were obtained from M. Kopf (MaxPlanck-Institut fur Immunobiologie) via Y. Iwakura (University of Tokyo) (33, 34) . Mice were maintained in the animal facilities of the Medical Sciences, Osaka University, under specific pathogen-free conditions. Animal experiments were performed following the guidelines of the Institutional Animal Care and Use Committees of the Graduate School of Frontier Biosciences and the Graduate School of Medicine of Osaka University. We just used 7-to 12-week old young animals for all the experiments without description in the figure legends.
Fetal liver transplantation
To analyze the T cells in gp130
FxxQ/FxxQ mice, which die after birth in neonate state, we transplanted fetal liver cells from gp130
FxxQ/FxxQ embryos at 14.5 days into lethally irradiated (950 rad) C57BL/6 SJL mice, as described previously (32) .
Antibodies and reagents
The following mAbs were used: allophycocyanin (APC)-conjugated anti-CD4 (BioLegend), anti-CD8 (eBiosciences), anti-CD19 (eBiosciences), IgG1 (BD), anti-IL-4 (BD) and anti-IFNc (BD); FITC-conjugated anti-CD4, anti-CD8, anti-B220, anti-Foxp3 (eBiosciences) and IgG2a (eBiosciences); PE-conjugated anti-CD4, anti-CD8, anti-CD44 (eBiosciences), anti-CD25 (eBiosciences), anti-IL-17 (eBiosciences) and IgG1 (eBiosciences); Cy5-conjugated anti-CD44 (eBiosciences), anti-CD8 (eBiosciences), streptavidin and Pacific Blue conjugate (Invitrogen) and biotin-conjugated anti-CD8, anti-CD19, antiCD11c, anti-B220, anti-NK1.1 and anti-CD45.1 (eBiosciences).
FACS analysis
Cultured or fresh whole or CD4
+ T cells from spleen and lymph nodes were prepared and incubated with fluorescenceconjugated antibodies (for specific staining and dump staining). FACS was performed on a FACSCalibur (Becton Dickinson) or a CyAn flow cytometer (Dako Cytomation).
Cell preparation and cell sorting
The lymph nodes and spleen from wild-type control or mutant mice were harvested and naive CD4 + CD44 Low T cells were purified using a MoFlo cell sorter (Dako Cytomation). The purity of the T cells was consistently >99%.
In vitro T-cell differentiation
Naive, sorted CD4 + T cells (5 3 10 5 ml À1 ) were cultured in vitro with or without anti-CD3 antibody (1 lg ml À1 ) (eBiosciences), IL-6 (1 lg ml À1 ) or TGFb (25 ng ml À1 ) in the presence of bone marrow-derived dendritic cells (1 3 10 5 ml À1 ) for 5 days.
Intracellular staining
In vitro assay. The recommended amount of Golgiplug (BD) was added to the culture during the last 6 h. Cells were stained with APC-conjugated anti-CD4 antibody, biotinconjugated anti-CD19, anti-NK1.1 and anti-CD45.1 antibodies (eBiosciences), followed by streptavidin-Pacific Blue treatment (Invitrogen). Next, the cells were fixed and permeabilized according to the manufacturer's directions (eBiosciences) and then stained with FITC-conjugated antiFoxp3 and PE-conjugated anti-IL-17 (TC11-18H10) antibodies (eBiosciences). Data were acquired on a CyAn flow cytometer (Dako Cytomation) and analyzed with FlowJo software.
In vivo assay. For Foxp3 staining, T cells from the lymph nodes and spleen were stained with APC-conjugated anti-CD4 (eBiosciences) antibody. The cells were fixed and permeabilized as above and then stained with FITC-conjugated anti-Foxp3 (eBiosciences) and biotin-conjugated anti-CD19 and anti-NK1.1 antibodies (eBiosciences) followed by streptavidin-Pacific Blue treatment (Invitrogen). For IL-17 staining, T cells from the lymph nodes and spleen were stimulated with plate-coated anti-CD3 antibody (20 lg ml À1 ) (eBiosciences) and anti-CD28 antibody (10 lg ml À1 ) (eBiosciences) for 6 h. The recommended amount of Golgiplug (BD) was added to the culture from the beginning of the incubation. The resulted cells were stained with FITC-conjugated anti-CD44 (eBiosciences), APC-conjugated anti-CD4 antibody and biotin-conjugated anti-CD19, anti-NK1.1 and anti-CD45.1 antibodies (eBiosciences) followed by streptavidin-Pacific Blue treatment (Invitrogen). The cells were then fixed in 4% PFA, permeabilized with PBS supplemented with 0.2% saponin and 0.05% sodium azide and stained with PE-conjugated anti-IL-17 (TC11-18H10) antibody (eBiosciences). Data were acquired on a CyAn (Dako Cytomation) and analyzed with FlowJo (for Foxp3) and Summit (for IL-17) software.
Real-time PCR
Total RNA was extracted from cells using an RNA isolation kit (Sigma). Complementary DNA was prepared as recommended and used as the template for quantitative PCR. The expression of RORct was evaluated using specific primers for RORct (5#-GGAGCTCTGCCAGAATGACC-3# and 5#-CAAGGCTCGAAACAGCTCCAC-3#) on a GeneAmp 5500 Sequence Detection System (Applied Biosystems). Expression was normalized to the expression of the housekeeping gene HPRT, as described previously (35) .
Statistical testing
Student's t-test (two tailed) was used for statistical testing between two groups.
CIA
CIA was brought about in DBA/1 J mice (Japan SLC) essentially according to the method previously described (36) . Mice were injected intra-dermally into the base of the tail with 200 lg of bovine type II collagen (CII) emulsified in CFA. Three weeks after the initial injection, a booster injection of 200 lg of bovine CII emulsified in CFA was performed intra-dermally into the base of the tail. Evaluation of clinical arthritis activity was carried out every 3 days from the second immunization for 27 days and its severity in the metacarpophalangeal wrist, metatarsophalangeal and ankle joints was scored as 0 = no arthritis, 1 = small degree of arthritis, 2 = light swelling, 3 = medium swelling and 4 = severe swelling and non-weight bearing. The arthritic score was the sum of the scores of all joints involved.
Measurement of IL-17 concentration in serum
IL-17 concentrations in sera were measured by ELISA kit (eBioscience) or Bio-plex system (Bio-Rad) according to the manufacture's protocols.
Results and discussions
STAT3-binding tyrosine residues but not the tyrosine for SHP2/Gab/ERK/MAPK activation in gp130 play a role in T h 17 development both in vitro and in vivo
To investigate which IL-6-gp130-mediated signaling pathway is critical for T h 17 development, we sorted naive CD4 + T cells from two types of knock-in mice: FxxQ mice, which transduce the SHP2/Gab/ERK/MAPK pathway but not the STAT3-mediated one via their mutant gp130, and F759 mice, which have a mutant gp130 that transduces the STAT3-dependent pathway but not the SHP2/Gab/ERK/MAPK one (25) (26) (27) .
We sorted naive CD4 + T cells from these mice and cultured them to generate T h 17. FxxQ CD4 + T cells expressed almost no IL-17 molecules, while F759 T cells expressed significantly more IL-17 than did CD4 + T cells from control animals in the culture (Fig. 1a and b) . The percentage of Foxp3 + CD4 + T cells increased in the culture of FxxQ CD4 + T cells with IL-6 in the presence of TGFb (Fig. 1a and c) . Since IL-6-gp130-mediated STAT3 activation is enhanced in F759 cells (data not shown) (27, 32) and defective in FxxQ CD4 + T cells, these results strongly suggested a critical role for STAT3 in the development of T h 17 as well as reciprocal development pathways for the development of T h 17 and Tregs in vitro.
We confirmed that a critical role of IL-6 for the development of T h 17 in vivo (Fig. 2a and b) , although we observed that a comparable level of Tregs (Foxp3 + CD4 + T cells) in IL-6KO comparing to wild-type control mice (Fig. 2c-e) . Next, we asked whether the same signaling pathway, via gp130, is required for the in vivo development of T h 17. We approached this question by examining T h 17 development in the FxxQ mice, and we observed almost no T h 17 in their lymph nodes and/or spleen ( Fig. 2a and b) . The percentage and number of Foxp3 + CD4 + T cells in the FxxQ mice were comparable to those of wild-type controls (Fig. 2c-e) . The F759 mice showed a comparable number of and a reduced percentage of T h 17 compared with wild type (Fig. 2a and b) .
Again, the percentage and number of Foxp3 
CD4
+ T cells in the F759 mice were comparable to those of wild-type controls (Fig. 2c-e) . Since the number of memory/activated CD44 high CD4 + as well as total CD4 + T cells is increased in the F759 mice (data not shown), but the absolute number of T h 17 (all of them are CD44 high CD4 + ) remains the same as wild-type mice, this suggests an increase in other T h populations more in F759 mice comparing to T h 17. Therefore, we analyzed T h 1 and T h 2 populations in F759 mice and showed that both percentage and the number of T h 1 population judged by the expression of IFNc but not T h 2 population were increased (Supplementary Figure 1 , available at International Immunology Online and data not shown). Taken together, all the in vitro and in vivo data demonstrated that STAT3-binding tyrosine residues in gp130, but not the tyrosine for SHP2/Gab/ERK/MAPK activation, are important in T h 17 development. Additionally, we suggested that IL-6-gp130-STAT3 pathway had a minimum effect on the development of Treg in the steady state in vivo, although it suppressed the development in vitro. (Fig. 1a-c) . Recently, RORct was reported to be a critical target of IL-6 and TGFb signaling to generate T h 17 (22) . Stimulation with IL-6 plus TGFb in the presence of T cell antigen receptor-mediated signaling synergistically increases RORct expression in naive CD4 + T cells (22) . Moreover, RORct expression is dramatically lower in the absence of either of these cytokines (22) . The expression of RORct was diminished in the STAT3-deficient CD4 + T cells (Fig. 1d) as well as FxxQ and gp130-deficient CD4 + T cells (Fig. 1d) , while RORct induction in F759 CD4
+ T cells enhanced compared with that in wild-type controls (Fig. 1d) . Because it was reported that STAT3 binds both the IL-17A and IL-17F promoters (18) , STAT3 might also play a role for the induction of IL-17 mRNA. Together with the results presented here, the existing evidence supports the idea that the STAT3-dependent expression of RORct provides at least in part the molecular basis for the critical role played by IL-6-gp130-STAT3 signaling in promoting the development of T h 17 from CD4 + T cells. Importantly, we showed that the in vivo development of T h 17 significantly decreased in gp130 flox/flox -and STAT3 flox/ flox -lckCre mice, (Fig. 2a and b) while we showed that a comparable level of Tregs in these mutants comparing to wildtype control mice (Fig. 2c-e) . Taken together, all these results establish a critical role for the IL-6-gp130-STAT3 pathway in vivo in the development of CD4 + T cells into T h 17 in vitro and in vivo.
Furthermore, our results showed that IL-6-gp130-STAT3 pathway in T cells had a minimum effect on in vivo Treg development. It is reported that Treg development takes place primarily in the thymus (37, 38) , but peripheral development, i.e. reciprocal generation of Treg versus T h 17 from mature peripheral CD4 + T cells is frequently suggested based entirely on in vitro data. The results here demonstrated that the reciprocal developmental pathways for the generation of T h 17 and Tregs observed in vitro do not operate in vivo at least in the steady state. Moreover, these data suggests that the major development of Treg occurs in the thymus via IL-6-independent manner and that any potential de novo peripheral induction plays a minor role if any at least in the steady state in vivo.
gp130-STAT3-mediated T h 17 development plays roles in autoimmune disease
It is important to evaluate the functional consequences of gp130-STAT3 pathway on T h 17 development in vivo. CIA is reported to be a T h 17-dependent autoimmune disease (13) . We used F759 strain for evaluating the functional consequences of IL-6-gp130-STAT3-signaling pathway on T h 17 development in vivo using this system. We established DBA background of F759 and control mice and then induced CIA. We showed that CIA was enhanced in F759 mice, whose gp130-mediated STAT3 signaling increased, compared with control animals (Fig. 3a) . Moreover, serum IL-17 concentration increased in F759 mice compared with wildtype controls after induction of CIA (Fig. 3b) . Thus, all the results presented here support the idea that T h 17, which is easily induced in F759 mice, is at least partially involved in a T h 17-mediated autoimmune disease, CIAinduced arthritis (13) .
In summary, the IL-6-gp130-STAT3-signaling pathway plays a role in autoimmune diseases at least in part through the induction of T h 17 development with a minimum effect on Treg development at least in the steady state in vivo.
Supplementary data
Supplementary Figure 1 is available at International Immunology Online.
